Short answer
Biogen (BIIB) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Biogen reported first-quarter 2026 results for the period ended March 31, 2026.
Biogen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Biogen reported first-quarter 2026 results for the period ended March 31, 2026
- Press release issued April 29, 2026 and furnished as Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $2.478B, up 2% YoY; GAAP EPS $2.15, up 31%; non-GAAP EPS $3.57, up 18%
- Growth products increased 12% YoY, led by LEQEMBI sales $168M, SKYCLARYS revenue $151M, and QALSODY revenue $33M
- Proposed Apellis acquisition targets commercialized retinal medicines and strengthens nephrology, with expected accretion in 2027
- 2026 non-GAAP EPS guidance reduced to $14.25–$15.25, reflecting approximately $1.00 of acquired IPR&D charges
- Full-year revenue expected to decline mid-single digits as multiple sclerosis declines offset growth-product expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biogen 8-K filings
Get the next BIIB 8-K as it lands
Follow BIIB for push alerts, or ask the research agent what this filing means.